{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:11:23Z","timestamp":1780395083040,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Shionogi, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.maturitas.2020.06.021","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T11:34:35Z","timestamp":1594380875000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)"],"prefix":"10.1016","volume":"142","author":[{"given":"Bin","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Biglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Panay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stora","family":"Djumaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martire","family":"Particco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemanth","family":"Kanakamedala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Altomare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.maturitas.2020.06.021_bib0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/WHE.14.9","article-title":"Treatment of vaginal atrophy","volume":"10","author":"Domoney","year":"2014","journal-title":"Womens Health (Lond. Engl.)"},{"issue":"3","key":"10.1016\/j.maturitas.2020.06.021_bib0010","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/GRF.0000000000000126","article-title":"Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations","volume":"58","author":"Lev-Sagie","year":"2015","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2020.06.021_bib0015","first-page":"23","article-title":"Management of vaginal atrophy: implications from the REVIVE survey","volume":"8","author":"Wysocki","year":"2014","journal-title":"Clin. Med. Insights Reprod. Heal."},{"key":"10.1016\/j.maturitas.2020.06.021_bib0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/IJWH.S110035","article-title":"Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy","volume":"8","author":"Palacios","year":"2016","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.maturitas.2020.06.021_bib0025","unstructured":"Introrosa (DHEA) Package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208470s000lbl.pdf. Accessed January 5, 2020."},{"issue":"8","key":"10.1016\/j.maturitas.2020.06.021_bib0030","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clbc.2017.05.008","article-title":"Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists","volume":"17","author":"Biglia","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.maturitas.2020.06.021_bib0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/IJWH.S158913","article-title":"Current treatment options for postmenopausal vaginal atrophy","volume":"10","author":"Naumova","year":"2018","journal-title":"Int. J. Womens Health"},{"issue":"10204","key":"10.1016\/j.maturitas.2020.06.021_bib0040","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.maturitas.2020.06.021_bib0045","series-title":"OSPHENA (ospemifene): Highlights of Prescribing Information","author":"Duchesnay Inc","year":"2019"},{"key":"10.1016\/j.maturitas.2020.06.021_bib0050","unstructured":"Senshio(R): Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/senshio-epar-product-information_en.pdf."},{"issue":"7","key":"10.1016\/j.maturitas.2020.06.021_bib0055","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/GME.0000000000000624","article-title":"Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo","volume":"23","author":"Eigeliene","year":"2016","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.maturitas.2020.06.021_bib0060","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0034-1367032","article-title":"Effects of ospemifene on breast tissue morphology and proliferation: a comparative study versus other selective estrogen receptor modulators in ovariectomized rats","volume":"46","author":"Kangas","year":"2014","journal-title":"Horm Metab Res = Horm und Stoffwechselforsch = Horm Metab."},{"key":"10.1016\/j.maturitas.2020.06.021_bib0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.maturitas.2018.11.017","article-title":"Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety","volume":"121","author":"Di Donato","year":"2019","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.maturitas.2020.06.021_bib0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.maturitas.2013.12.005","article-title":"Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women","volume":"77","author":"Simon","year":"2014","journal-title":"Maturitas."},{"issue":"4","key":"10.1016\/j.maturitas.2020.06.021_bib0075","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"issue":"18","key":"10.1016\/j.maturitas.2020.06.021_bib0080","first-page":"3934","article-title":"Ospemifene: a safe treatment of vaginal atrophy","volume":"20","author":"Del Pup","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.maturitas.2020.06.021_bib0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13697137.2013.834493","article-title":"Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy","volume":"17","author":"Goldstein","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2020.06.021_bib0090","first-page":"1939","article-title":"Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause","volume":"9","author":"Wurz","year":"2014","journal-title":"Clin. Interv. Aging."},{"key":"10.1016\/j.maturitas.2020.06.021_bib0095","unstructured":"IBM Watson Health. IBM MarketScan Research Databases for Health Services Researchers. 2019."},{"issue":"5","key":"10.1016\/j.maturitas.2020.06.021_bib0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"issue":"1","key":"10.1016\/j.maturitas.2020.06.021_bib0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Forbes","year":"2008","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2020.06.021_bib0110","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000001698","article-title":"Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer","volume":"265","author":"Wong","year":"2017","journal-title":"Ann. Surg."},{"issue":"9793","key":"10.1016\/j.maturitas.2020.06.021_bib0115","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2020.06.021_bib0120","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.2147\/OTT.S142698","article-title":"ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy","volume":"10","author":"Song","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"4","key":"10.1016\/j.maturitas.2020.06.021_bib0125","article-title":"Toronto workshop on late recurrence in estrogen receptor\u2013positive breast cancer: part 1: late recurrence: current understanding, clinical considerations","volume":"3","author":"Dowling","year":"2019","journal-title":"JNCI Cancer Spectr."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851222030311X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851222030311X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:17:11Z","timestamp":1759915031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851222030311X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"alternative-id":["S037851222030311X"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2020.06.021","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2020.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}